|
[½»Á÷]
¡¾×ªÌû¡¿ÃÀ¹ú×Ô1995µ½2008ÄêÉÏÊеĿ¹°©ÐÂÒ©ÒÑÓÐ3È˲ÎÓë
ÃÀ¹ú×Ô1995µ½2008ÄêÉÏÊеĿ¹°©ÐÂÒ©
Drugs Approved in 2008 ¡¡
Treanda (bendamustine hydrochloride) ; ÖÎÁÆÂýÐÔÁÜ°Íϸ°ûÐÔ°×Ѫ²¡; Cephalon; Approved 2008 3ÔÂ
Drugs Approved in 2007
Hycamtin (topotecan) ; ÖÎÁÆСϸ°û·Î°© ÍíÆÚ×Ó ¹¬¾±°© Âѳ²°© ,GlaxoSmithKline; Approved October 2007
Ixempra (ixabepilone) ; ͨ¹ýFDAµÄÅú×¼Óà ×÷Ò»ÏßÒ©ÎïÖÎÁÆÍíÆÚÈéÏÙ°©; Bristol Myers Squibb; October 2007
Tykerb (lapatinib) ; ÈéÏÙ°©ÍíÆÚÐÂÒ© Tykerb,ÊǸðÀ¼ËØÊ·¿Ë¹«Ë¾ÑÐÖƵġ£ ÁÙ´²ÊÔÑéÏÔʾ,¶ÔÓÚÄÇЩÒѶÔÂÞÊϵĺÕÈüÍ¡(Herceptin)²úÉúÄÍÒ©ÐÔµÄHER2ÐÍÈé°©»¼Õß,ÕâÖÖÐÂÒ©ÓкܺõÄÁÙ´²Ð§¹û¡£
Torisel (temsirolimus) ; ÍíÆÚÉö°©×îÐÂÒ©Î ÊÇΨһÉÏÊеÄÌØÒìÐÔÒÖÖÆmTOR¼¤Ã¸µÄÒ©Îï,mTOR¼¤Ã¸Êǵ÷½Úϸ°ûÔöÖµ¡¢Éú³¤ºÍϸ°û´æ»îÖØÒªµÄµ°°×ÖÊ¡£Äܹ»ÓÐЧÒÖÖƺ͵÷½Úµ°°×ϸ°ûÔöÖ³¡¢Ï¸°ûÉú³¤ºÍϸ°û ´æ»îÂÊ,ÊÇÄ¿Ç°µÚÒ»¼ÁÓÃÓÚÖÎÁÆ°©Ö¢µÄ×¢Éä¼Á¡£
Tasigna (nilotinib hydrochloride monohydrate) ; ÖÎÁÆÂýÐÔ¹ÇËèÐÔ°×Ѫ²¡µÄÐÂÒ© Novartis; 2007Äê10 ÔÂÅú×¼ÉÏÊÐ
vista (raloxifene hydrochloride) ; ÖÎÁƺÍÔ¤·À¹ÇÖÊÊèËÉÒÔ¼°¼õÉÙ¾ø¾ÆÚ¸¾Å®ÈéÏÙ°©µÄ·¢Éú£»Eli Lilly; 07Äê9 ÔÂÉÏÊС£
Drugs Approved in 2006
Sutent (sunitinib) ; ÖÎÁÆÉöϸ°ûÖ×ÁöºÍ賦µÀ¼äÖÊÖ×ÁöÐÂÒ©¡£PfizerÉú²ú; 2006Äê1ÔÂÅú×¼ÉÏÊС£
Sprycel(dasatinib) ; ÓÃÓÚÖÎÁÆÁ½ÖÖеÄÊÊÓ¦Ö¢£º¶ÔÒÁÂíÌæÄáµÈÒ»ÏßÒ©ÎﻯÁƲ»Ãô¸ÐµÄ¸÷ÆÚÂýÐÔÁ£Ï¸°û°×Ѫ²¡(CML)£¬ÒÔ¼°¶ÔÆäËûÁÆ·¨ÎÞЧ»ò²»ÄÜÄÍÊܵÄPhȾɫÌåÑôÐԵļ±ÐÔÁÜ°Íϸ°û°×Ѫ ²¡(ALL)¡£
Vectibix (panitumumab) ÐÖúÖÎÁÆ´ó³¦Ö±³¦°©ÒÑÀ©É¢µ½ÆäËü²¿Î»µÄ»¼Õß ¡£ ¶ÔÖ×ÁöÓмõ »º¶ñ»¯µÄЧÓà (ÔÚijЩ²¡ÀýÉõÖÁÄÜËõСÖ×Áö)
Drugs Approved in 2005
Arranon (nelarabine) ; ÖÎÁƼ±ÐÔ³ÉÁÜ°Íϸ°ûÐÔ°×Ѫ²¡ Tϸ°ûÁÜ°ÍÁöÐÂÒ© GlaxoSmithKlineÉú²ú; 05Äê10 Ô¡£
Nexavar (sorafenib) ; È«ÇòÊ׸ö¿Ú·þ¶à¼¤Ã¸ÒÖÖƼÁ£¬ÖÎÁÆÍíÆÚÉöϸ°û°©µÄÒ©ÎBayer/OnyxÉú²ú; 05Äê12 Ô¡£
Revlimid (lenalidomide) ; ÖÎÁÆÇáÖжÈ-1-risk ¹ÇËèÔöÉúÒì³£×ÛºÏÕ÷ºÏ; CelgeneÉú²ú; 2005Äê12ÔÂÅú×¼ÉÏÊС£
Abraxane ( PACLITAXEL PROTEIN-BOUND ) ; ÃÀ¹úÖÆÒ©»ï°é¹«Ë¾(American Pharmaceutical Partners,APP)ºÍÃÀ¹úÉúÎï¿Æѧ(American BioScience)½üÈÕÐû²¼£¬ÃÀ¹úFDAÅú×¼ÁËAbraxaneÓÃÓÚÖÎÁÆתÒÆÐÔÈéÏÙ°©µÄÐÂÒ©ÉêÇë¡£Á½¼Ò¹«Ë¾ÀûÓÃËûÃǵÄרÀûÄÉÃ×¼¼Êõ,°ÑAbraxaneµÄ»îÐԳɷÖ×Ïɼ´¼(Paclitaxel)ºÍÖ»Óкìϸ°û1%´óСµÄÄÉÃ×°×µ°°×¿ÅÁ£½áºÏÔÚÒ»Æ𣬴Ӷø±ÜÃâÁ˸÷ÖÖÈܽâ¿ÉÄÜ¡£AbraxaneÊǵÚÒ»·ÇÈܽâÄÉÃ×°×µ°°×½áºÏ»¯ÁÆÒ©Î¿ÉÒÔÓÐЧµÄÀûÓð׵°°×ÊÜÌåÄÚÔÚ;¾¶´«ÊäÒ©Îïͨ¹ýÖ×ÁöÐÂÉúѪ¹ÜÄÚƤϸ°û±Ú¡£Óëµ¥´¿×Ïɼ´¼Ïà±È£¬Æä×÷ÓÃʱ¼ä³¤£¬¸±×÷ÓÃС¡£
Drugs Approved in 2004
Alimta (pemetrexed for injection) ; ÖÎÁƶñÐÔÐØĤ¼äƤÁö£¬li Lilly Éú²ú; 2004Äê¶þÔÂÅú×¼ÉÏÊÐ
Avastin (bevacizumab) ; ÖÎÁƶñÐÔÖ±³¦°©; GenentechÉú²ú; 2004Äê2ÔÂÅú×¼ÉÏÊÐ
Erbitux (cetuximab) ; ÖÎÁÆEGFR-±íÏֵĶñÐԽ᳦ֱ³¦°©; Imclone / Bristol-Myers SquibbÉú²ú; 2004Äê¶þÔÂÉÏÊÐ
Sensipar (cinacalcet) ; ÖÎÁƼ̷¢ÐÔ¼××´ÅÔÏÙ¹¦ÄÜ¿¹½ø(¼××´ÅÔÏÙ°©)ÒýÆðµÄ¸ßѪ¸Æ; AmgenÉú²ú; 2004ÄêÈýÔÂÉÏÊÐ
Clolar (clofarabine) ; ÓÃÓÚÖÎÁÆС¶ù¼±ÐÔÁÜ°Íϸ°ûÐÔ°×Ѫ²¡; Genzyme; Éú²ú; 2004Äê12ÔÂÅú×¼ÉÏÊÐ
Tarceva (erlotinib, OSI 774) ; ÓÃÓÚÖÎÁƶñÐÔ£¬ÄÑÖÎÐÔ·ÇСϸ°û·Î°©; Genentech, OSI PharmaceuticalsÉú²ú; 04Äê11
Drugs Approved in 2003
Emend (aprepitant) ; ÖÎÁÆ»¯ÁƲ¡È˵ĶñÐÄ£¬Å»ÍÂ; MerckÉú²ú; 2003Äê3ÔÂÅú×¼ÉÏÊÐ
Iressa (gefitinib) ; ÖÎÁÆ·ÇСϸ°û·Î°©µÄÐÂÒ©£¬AstraZenecaÉú²ú; 2003Äê5ÔÂÅú×¼ÉÏÊÐ
Aloxi (palonosetron) ; Ô¤·ÀÖ×Áö»¯ÁƲ¡È˵ĶñÐÄ£¬Å»Í ; MGI Pharma / Helsinn HealthcareÑз¢Éú²ú; 2003Äê8ÔÂ
UroXatral (alfuzosin HCl extended-release tablets);ÖÎÁÆÁ¼ÐÔÇ°ÁÐÏÙÔöÉúµÄ¸÷ÖÖÖ¢×´; Sanofi-SynthelaboÉú²ú; 2003Äê6ÔÂÅú×¼ÉÏÊÐ
Velcade (bortezomib) ; ÖÎÁÆÖÁÉÙ½ÓÊܹý¶þÖÖÒÔÉÏÁÆ·¨µÄ¶à·¢ÐÔ¹ÇËèÁöµÃ²¡ÈË; Millennium PharmaceuticalsÉú²ú; 2003Äê5ÔÂÅú×¼ÉÏÊÐ
exxar ; ÖÎÁÆCD20ÑôÐÔ£¬µÄСÄÒÐÔ·Ç»ô½Ü½ðÊÏÁÜ°ÍÁö»¯ÁƸ´·¢µÄ²¡ÈË; CorixaÉú²ú; 2003Äê6ÔÂÅú×¼ÉÏÊÐ
Drugs Approved in 2002
Eligard (leuprolide acetate) ; Ç°ÁÐÏÙ°©¿¹°©ÐÂÁÆ·¨ ÓÃÓÚÇ°ÁÐÏÙ°©µÄ»º½âÖÎÁÆ ; Atrix Laboratories; 2002Äê 1 ÔÂÅú×¼ ÉÏÊÐ Eloxatin (oxaliplatin/5-fluorouracil/leucovorin); ÓÃÓڽ᳦ºÍÖ±³¦°©Ö¢µÄÖÎÁÆ ; Sanofi-SynthelaboÉú²ú; 2002Äê8ÔÂÅú×¼ ÉÏÊÐ Faslodex (fulvestrant) ; ÖÎÁƼ¤ËØÊÜÌåÑôÐԵĴúлתÒÆÐÔÈéÏÙ°©; AstraZenecaÉú²ú; 02Äê4ÔÂÅú
Gleevec ; ÖÎÁÆѪ°© ( ÂýÐÔ¹ÇËèÐÔ°×Ѫ²¡) chronic myelogenous leukemia (CML) ·Ç³£ÓÐЧ£¬²¢¶ÔÖÎÁÆ賦»ùµ×ϸ°û°© (gastrointestinal stromal tumor) (GIST) ¡¢Ç°ÁÐÏÙ°©µÈÒàÓÐÃ÷ÏÔЧ¹û ; ÓÉ Novartis ¿ª·¢Éú²ú ; 2002 Äê 2 ÔÂÅú×¼ 賦°©ÐÂÊÊÓ¦Ö¢
Neulasta ; ½µµÍÓÉÓÚ»¯ÁÆÒýÆðµÄÖÐÐÔ°×ϸ°û¼õÉÙÖ¢¶øµ¼ÖµĸÐȾ»ú»á Amgen; 2002Äê1ÔÂÅú×¼ ÉÏÊÐ
SecreFlo (secretin) ; ÓÃÓÚÒÈÏÙ¹¦ÄÜÕï¶ÏºÍÖÎÁÆθÃÚËØÖ×Áö; Repligen; 2002Äê4ÔÂÅú×¼ ÉÏÊÐ
Zevalin (ibritumomab tiuxetan) ; ÖÎÁÆ·Ç»ô½Ü½ðÊÏÁÜ°ÍÈâÁö ; IDEC Pharmaceuticals; 2002 Äê 2 ÔÂÅú×¼ ÉÏÊÐ
Zometa (zoledronic acid) ; ÖÎÁƶ෢ÐÔ¹ÇËèÁö ʵÌåÖ×Áöµ¼Ö嵀 ¹Ç»µËÀ ; Novartis; 2002 Äê 2 ÔÂÅú×¼ ÉÏÊÐ
Drugs Approved in 2001
Campath ; ×¢ÉäÓÃÒ©ÖÎÁÆB-ϸ°ûÂýÐÔÁÜ°ÍÐÔ°×Ѫ²¡; ÓÉBerlex Laboratories ¿ª·¢Éú²ú ; 2001Äê5ÔÂÅú×¼ÉÏÊÐ
Femara (letrozole) Ƭ¼Á; Í£¾ºó¸¾Å®î¾»¼×ªÒÆÐÔÈé°©µÄµÚÒ»ÏßÖÎÁÆÒ©Îï; ÓÉNovartis ¿ª·¢Éú²ú ; 01Äê1ÔÂ
Gleevec ; ÖÎÁÆѪ°© ( ÂýÐÔ¹ÇËèÐÔ°×Ѫ²¡) chronic myelogenous leukemia (CML) ·Ç³£ÓÐЧ£¬²¢¶ÔÖÎÁÆ賦»ùµ×ϸ°û°© (gastrointestinal stromal tumor) (GIST) ¡¢Ç°ÁÐÏÙ°©µÈÒàÓÐÃ÷ÏÔЧ¹û ; ÓÉNovartis ¿ª·¢Éú²ú ; 2001Äê5ÔÂÅú×¼ÉÏÊÐ
Kytril (granisetron) Solution ; »¯ÁƲ¡È˵ĶñÐÄ£¬Å»ÍÂ; Hoffmann-La RocheÉú²ú; 2001Äê6ÔÂÅú×¼ÉÏÊÐ
Trelstar LA ; ¼¡Èâ×¢ÉäÕë¼Á£¬ÀÏÄêÇ°ÁÐÏÙ°©Ö¢ÖÎÁÆ; Debiopharm S.A.;Éú²ú; 2001Äê6ÔÂÅú×¼ÉÏÊÐ
Xeloda ; Ö±³¦½á³¦°©Ö¢¿Ú·þ»¯ÁÆÒ©; Hoffman-La RocheÉú²ú; 2001Äê5ÔÂÅú×¼ÉÏÊÐ
Zometa (zoledronic acid) ; ÓÃÓÚ¶ñÐÔ¸ßѪ¸ÆÖ¢µÄÖÎÁÆFor the treatment of hypercalcemia of malignancy; NovartisÉú²ú; 2001Äê8ÔÂÅú×¼ÉÏÊÐ
Drugs Approved in 2000
Mylotarg ( gemtuzumab ozogamicin) ; CD33 ÑôÐԵļ±ÐÔËèÐÔ°×Ѫ²¡(AML); WyethÉú²ú; 2000Äê5ÔÂÅú×¼ÉÏÊÐ
Trelstar Depot (Injectable Triptorelin Pamoate) ; ½øÐÐÐÔÇ°ÁÐÏÙ°©¹ÃÏ¢ÁÆ·¨ ; Debio Rechereche Pharmaceutique SA (c/o Target Research Associates)Éú²ú; 2000Äê6ÔÂÅú×¼ÉÏÊÐ
Trisenox (arsenic trioxide) ; Ò»ÖÖº¬ÉéµÄÒ©ÎҲ¾ÍÊÇÎÒÃÇË×³Æ µÄÅø˪£¬¿ÉÒÔÓÃÀ´ÖÎÁÆÒ»¸öÖÂÃüÐԵĺ±¼û¼²²¡©¤¼±ÐÔÇ°¹ÇËæϸ°ûÐÔ°×Ѫ²¡ £¬ÕâÊÇÃÀ¹ú½ü°ÙÄêÀ´Ê״κË×¼µÄÉéÁÆ·¨¡£ÊÊÓ¦³ÉÄ껼Õߵĸ´·¢/Íç¹ÌÐͼ±ÐÔÔçÓ×Á£Ï¸°û°×Ѫ²¡ÖÎÁÆ(APL)Cell Therapeutics Éú²ú; 2000Äê9ÔÂÅú×¼ÉÏÊÐ
Viadur (leuprolide acetate implant) ;ÓÃÓÚ ½øÐÐÐÔÇ°ÁÐÏÙ°©ÌÛÍ´»º½â ; ALZA CorporationÉú²ú; 2000Äê3ÔÂÅú×¼ÉÏÊÐ
Drugs Approved in 1999
Aromasin Tablets; Exemestane Tablets, 25 mg; Èé°©»¼Õ߸ķþ AROMASIN ¸üÓпÉÄܱ£³Ö°©Ö¢²»¸´·¢ Pharmacia & UpjohnÉú²ú; 1999Äê10ÔÂÅú×¼ÉÏÊÐ
Busulflex ; ºÏ²¢ÓÃÓÚ°×Ѫ²¡µÄ×ÛºÏÖÎÁÆ ; Orphan Medical, Inc.Éú²ú; 1999Äê2ÔÂÅú×¼ÉÏÊÐ
Doxil (doxorubicin HCl liposome injection); ÖÎÁÆÍç¹ÌÐÔÂѳ²°©¡£ÊÊÓÃÓÚÄÇЩÔø¾Óùýµ±½ñÒ»Á÷µÄ»¯ÁÆ·½·¨Ò½ÖιýµÄÍç¹ÌÐÔÂѳ²°©»¼Õß¡£Íç¹ÌÐÔÂѳ²°©±»¶¨ÒåΪ£ºÔÚÖÎÁƹý³ÌÖлòÍê³ÉÖÎÁƺó6¸öÔÂÀﲡÇé²»¶Ï¶ñ»¯µÄ¼²²¡¡£Treatment for ovarian cancer that is refractory to other first-line therapies; Alza Corp.Éú²ú; 1999Äê6ÔÂÅú×¼ÉÏÊÐ;
Ellence ; epirubicin hydrochloride; ¿É ÖÎ ÁÆ Ôç ÆÚ ÓÉ Èé °© À© É¢ ÖÁ ÁÜ °Í ½á °© Ö× µÄ Å® ÐÔPharmacia & UpjohnÉú²ú; 1999Äê9ÔÂÅú×¼ÉÏÊÐ;
Ethyol (amifostine); ÖÎÁÆÖ×Áö·ÅÁƲ¡È˵ĿÚÇ»¸ÉÔïÖ¢(dry mouth); U.S. Bioscience and Alza Corp.Éú²ú; 99Äê6ÔÂ
Temodar ; ÖÎÁÆÄÑÖÎÐÔÍËÐÐÐÔÐÇ״ϸ°ûÁö; Schering-PloughÉú²ú; 1999Äê8ÔÂÅú×¼ÉÏÊÐ;
UVADEX Sterile Solution; ÖÎÁƵÄƤ·ôTϸ°ûÁÜ°ÍÁö(Cutaneous T cell lymphoma, CTCL)µÄƤ·ô¸Ä±ä; Therakos, Inc.Éú²ú; 1999Äê2ÔÂÅú×¼ÉÏÊÐ;
Zofran ODT; Ô¤·ÀÖ×Áö»¯ÁƺͷÅÁƲ¡È˵ĶñÐÄ£¬Å»ÍÂ; Glaxo Wellcome Inc.Éú²ú; 1999Äê1ÔÂÅú×¼ÉÏÊÐ;
Drugs Approved in 1998
Actiq ; ÖÎÁÆ°©Ö¢ÌÛÍ´ Pain; Anesta CorporationÉú²ú; 1998Äê11ÔÂÅú×¼ÉÏÊÐ;
Anzemet ;ÖÎÁÆÔ¤·ÀÖ×Áö»¯ÁƺÍÊÖÊõ²¡È˵ĶñÐÄ£¬Å»ÍÂ; 1998Äê2ÔÂÅú×¼ÉÏÊÐ
Camptosar ; ÖÎÁÆÖ±³¦½á³¦°©Ö¢; Pharmacia & UpjohnÉú²ú; 1998Äê10ÔÂÅú×¼ÉÏÊÐ
Gemzar ; ÖÎÁƷΰ©; Eli LillyÉú²ú; 1998Äê8ÔÂÅú×¼ÉÏÊÐ
Herceptin ; ÖÎÁƶñÐÔÈé·¿°©; GenentechÉú²ú; 1998Äê10ÔÂÅú×¼ÉÏÊÐ
Neupogen ; ÖÎÁÆÖ×Áö²¡ÈË»¯Áƺó°×ϸ°û»Ö¸´»ºÂý; AmgenÉú²ú; 1998Äê4ÔÂÅú×¼ÉÏÊÐ
Nolvadex ; ÖÎÁÆÈéÏÙ°©; Zeneca PharmaceuticalsÉú²ú; 1998Äê10ÔÂÅú×¼ÉÏÊÐ
Photofrin ; ÖÎÁÆÔçÆÚ·ÇСϸ°û·Î°© microinvasive endobronchial non-small cell lung cancer; QLT TherapeuticsÉú²ú; 1998Äê1ÔÂÅú×¼ÉÏÊÐ
Proleukin ; ÖÎÁÆ´úлÐÔºÚÉ«ËØÁö Chiron CorporationÉú²ú; 1998Äê1ÔÂÅú×¼ÉÏÊÐ
Sclerosol Intrapleural Aerosol ; ÖÎÁƶñÐÔÐØÇ»»ýÒº; Bryan CorporationÉú²ú; 1998Äê1ÔÂÅú×¼ÉÏÊÐ
Valstar ; ÖÎÁÆ°òë×°©; Anthra PharmaceuticalsÉú²ú; 1998Äê10ÔÂÅú×¼ÉÏÊÐ
Xeloda ; ÖÎÁƽøÐÐÐÔÈé·¿°©Áö; Hoffmann LaRocheÉú²ú; 1998Äê4ÔÂÅú×¼ÉÏÊÐ
Zofran ; ÖÎÁƳÉÄêÈËÊÖÊõºóµÄ¶ñÐÄ£¬Å»ÍÂ; Glaxo WellcomeÉú²ú; 1998Äê4ÔÂÅú×¼ÉÏÊÐ
Drugs Approved in 1997
Anzemet ; Treatment for emesis; Hoechst Marion Roussel; Approved September 1997
Bromfenac ; Management of acute pain; Duract, Wyeth-Ayerst; Approved July 1997
Femara ; Treatment for breast cancer; Novartis; Approved July 1997
Gliadel Wafer (polifeprosan 20 with carmustine implant) ; Treatment for brain cancer; Rhone-Poulenc Rorer, Inc. and Guilford Pharmaceuticals Inc.; Approved February 1997
Intron A ; Treatment for non-Hodgkin's lymphoma; Schering-Plough Corp.; Approved December 1997
Kytril ; Prevention of nausea and vomiting associated with chemotherapy; SmithKline Beecham; 1997£¨11£©
Lupron Depot ; Treatment for prostate cancer; Tap Holdings; Approved July 1997
Miraluma test ; Test for breast cancer; DuPont Pharma Radiopharmaceuticals; Approved May 1997
Neumega ; Treatment for thrombocytopenia; Genetics Institute; Approved November 1997
Quadramet (Samarium Sm 153 Lexidronam Injection) ; Treatment for pain associated with bone cancer; DuPont Merck Pharmaceutical Company; Approved March 1997
Rituxan ; Treatment for non-hodgkin's lymphoma; Idec Pharmaceuticals; Genentech Inc.; Approved 11ÔÂ1997
Taxol ; Treatment for AIDS-related Kaposi's Sarcoma; Bristol-Myers Squibb; Approved August 1997
Drugs Approved in 1996
Anexsia ; Treatment for chronic pain; Mallinckrodt Group; Approved August 1996
Aredia (pamidronate disodium for injection) ; Treatment for osteolytic bone metastases of breast cancer; Chiron Therapeutics, Ciba Pharmaceuticals; Approved August 1996
Arimidex (anastrozole) ; Treatment for advanced breast cancer in postmenopausal women; Zeneca; Approved 1ÔÂ1996
Camptosar Injection ; Treatment for metastatic colorectal cancer; Pharmacia & Upjohn; Approved June 1996
CEA-Scan; Diagnostic imaging product for colorectal cancer; Immunomedics; Approved April 1996
Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection) ; Treatment of meningeal leukemia or lymphocytic lymphoma; Orphan Medical, Inc.; Approved October 1996
Eulexin (flutamide) ; Treatment for prostate cancer; Schering-Plough Corporation; Approved June 1996
Feridex I.V. ; Contrast agent for magnetic resonance imaging of liver lesions; Advanced Magnetics; 1996Äê 2ÔÂ
GastroMARK ; Contrast agent for magnetic resonance imaging of the gastrointestinal tract; Advanced Magnetics; Approved May 1996
Gemzar (Gemcitabine HCl) ; Treatment for pancreatic cancer; Eli Lilly; Approved May 1996
Hycamtin (topotecan hydrochloride) ; Treatment for metastatic ovarian cancer; SmithKline Beecham; Approved May 1996
Kadian ; Treatment for chronic moderate to severe pain; Purepac Pharmaceutical; Approved July 1996
Leukine (sargramostim) ; Treatment for the replenishment of white blood cells; Immunex Corporation; 1996£¨11£©
Lupron Depot (leuprolide acetate for depot suspension) ; Treatment for advanced prostate cancer; Abbott Laboratories; 1996£¨01£©
Photodynamic Therapy; Photodynamic therapy device for the treatment of esophageal cancer; Sanofi Winthrop, QLT PhotoTherapeutics; Approved January, 1996
Taxotere (Docetaxel) ; Treatment for locally advanced or metastatic breast cancer; Rhone Poulenc Rorer; 1996£¨05£©
UltraJect ; Treatment for chronic pain; Mallinckrodt Group; Approved August 1996
Visipaque (iodixanol) ; Diagnostic contrast agent; Nycomed; Approved April 1996
Zoladex (10.8 mg goserelin acetate implant) ; Treatment for advanced prostate cancer; Zeneca; Approved January 1996
Drugs Approved in 1995
Ethyol (amifostine) ; Treatment to reduce renal toxicity associated with chemotherapy in subjects with advanced ovarian cancer; Alza Pharmaceuticals, U.S. Bioscience; Approved December 8, 1995
Intron A (Interferon alfa-2b, recombinant) ; An adjuvant treatment to surgery in subjects at high risk for systemic recurrence of malignant melanoma; Schering-Plough; Approved December 1995
Leukine (sargramostim) ; Treatment for mobilizing peripheral blood progenitor cells for use after transplantation.; Immunex Corp.; Approved on November 24, 1995
Self-examination breast pad; Self-examination breast pad; Inventive Products Inc.; Approved on December 1995 |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
» ²ÂÄãϲ»¶
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍƼö£¬¶ÔÄúͬÑùÓаïÖú:
|